English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 September 2024, 18:00 HKT/SGT
Share:
    

Source: Moolec Science SA
Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

Luxembourg, Sept 5, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ and Piggy Sooy™ US Harvest AnnouncementGLASO™ and Piggy Sooy™ US Harvest Announcement

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec's CPG customer, production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec's GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec's US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: "Our commitment to scaling Moolec's Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology." He then finished by remarking: "One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO2 emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system."

Contact Information
Press & Media
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files

Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October - 2024.09.05

SOURCE: Moolec Science



Topic: Press release summary
Source: Moolec Science SA

Sectors: Agritech, Food & Beverage
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Moolec Science SA Related News
July 15, 2024 19:00 HKT/SGT
Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025
May 30, 2024 18:00 HKT/SGT
Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update
Apr 30, 2024 18:00 HKT/SGT
Moolec Announces New Patent Granting in the United States for Molecular Farming Platform
Apr 22, 2024 20:00 HKT/SGT
Molecular Farming Company to Achieve USDA Approval for Plant-Grown Animal Proteins
Mar 13, 2024 18:56 HKT/SGT
Moolec Science發布2024財年第二季業務更新
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575